drugset / Trial / NCT00380159
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
Phase 2
Completed
4 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety of 48 weeks of treatment with 10 milligrams (mg) of elvucitabine in combination with background antiretroviral therapy (ART) in participants who completed Study ACH443-014A and meet the inclusion and exclusion criteria.
Timeline
- Start
- 2006-09
- Primary completion
- 2008-12
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elvucitabine | Small molecule | 10 mg | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | emtricitabine | Other / unclassified | — | — |